Mark Schoenebaum was a brilliant and successful Wall Street research analyst who fundamentally changed the way sell-siders cover biotech stocks. More importantly, Mark was a remarkably nice guy. Wall Street is not known for warm and fuzzy people, but Mark smashed that mold. He was kind and funny. He was gregarious and uncommonly generous to colleagues, friends, and even strangers.

Most of the biotech investment community first heard about Mark’s death via a gut-wrenching email sent by his friend and former colleague Umer Raffat on Sunday evening.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Adam, your article was perfect. I knew Mark for >15 years so I feel qualified to opine. And more importantly, his legacy deserves this remembrance. Bravo!!!

  • Adam – beautifully written. Mark will be missed. (Mary – our hearts are with you and your family.)

  • Adam, your eloquent piece about my beloved son, Mark, will be in my memory forever. You nailed it! Im so glad that “Wall Streeters” knew the real Mark. Thank you

    • Mary — I am so sorry for your loss. I hope this piece gives you some small comfort in knowing how much Mark was admired and respected by the biotech community. It was an honor to know him and call him a friend. He is truly missed.

  • Mark was an amazing guy and research analyst. When I started my career he always made himself available to talk and share his insights and learnings. Biotech lost a standup guy. He will be missed by many of us.

  • Ditto! Adam, you beautifully captured what made Mark so incredible to so many people. Thank you. He was an extraordinary analyst, teacher and person and knew just how to make analyzing biotech data fun.

  • As far as I can tell, Mark single-handedly redefined what it meant to be a sell-side analyst. All that stuff folks do routinely today, he created. I’m shocked and saddened.

  • Thanks Adam for expressing what so many of us are feeling today. Mark was one of a kind (often imitated now). It did not take long after I started covering biotech in 2002 to figure out that Mark was a first call go-to guy for so many complicated stories. Quick to respond, generous with his time and very funny. A tough combo to beat. Gone far too soon.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy